AZN Jan 2026 80.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

9.30

-1.10

(-10.58%)

As of 10:44AM EDT. Market open.

Loading interactive chart…

Zacks
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Business Wire
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
CAMBRIDGE, England, May 27, 2024--Dato-DXd TL01 OS HLR
Zacks
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.